Pharmaceutical

Love Pharma

CSE:LUV

Bringing Psychedelic Therapies and Pharmaceutical Alternatives to Market

Company Highlights

  • Love Pharma specializes in sexual health and wellness by distributing products infused with CBD and THC directly to consumers. It holds exclusive licenses to produce, market, package, sell and distribute these patent-protected products throughout North America, the United Kingdom and Europe.
  • The company is investing in creating sustainable long-term sales through strategic distributor partnerships
  • The launch products, Bloom and Auralief, are licensed for retail sales, creating an immediate opportunity for revenue
  • Love Pharma has already planned domestic and international expansion
  • The management team has an established history of success with cannabis and pharmaceutical products
  • The company plans to create research-backed products that make use of psychedelics and nutraceuticals
  • Once the company is publicly listed, plans are already in place to rapidly distribute products and quickly generate revenue
  • Love Pharma completed the acquisition of MicroDoz Theraphy Inc.
Press Releases

Overview

Attitudes about sexual wellness are changing, and the market is directly reflecting these changes. Sexual wellness is a general term that refers to the physical, mental and social well-being of an individual. This broad market is made up of any product related to sexual wellness, such as supplements, contraceptives, lingerie, and other holistic products.

A report conducted by KBV Research estimates that the global sexual wellness market size will reach US$125.1 billion by 2026, with the potential for a 12.4 percent CAGR during this period. This steady growth has been driven by a renewed interest in sexual discovery, rising prevalence of sexually transmitted diseases, and the broader shift to ecommerce.

Love Pharma (CSE:LUV) creates innovative science-driven products to cater to the ever-evolving space of sexual health and wellness. It aims to deliver breakthrough products that enhance the everyday life of the end-user by increasing intimacy and pleasure.

The company is on a mission to offer new and trustworthy products that make use of “new age" pharmaceuticals that are backed by thorough scientific research. Love Pharma will launch with products that focus on nutraceuticals, which are pharmaceutical alternatives that have naturally occurring benefits, such as CBD and THC. It will launch with two products: Bloom and Auralief. Additional products are already under development.

Bloom is a CBD and/or THC-infused arousal gel that is intended for female pleasure. According to the KBV report, women are the fastest-growing segment of the sexual wellness market. They attribute this trend to the increase in working women along with more availability of sex education. While female contraceptives will make up a large part of this growing segment, other products for women may perform well. The Bloom arousal gel does not have any psychoactive effects and is designed to enhance blood flow, creating physical stimulation with the ultimate goal of increasing pleasure.

In May 2021, Love Pharma partnered with Potent Ventures (OTCMKTS: POTVF) to help launch Love Pharma's flagship projects in the United States. The United States sexual wellness market is expected to reach US$15.9 billion by 2027, making this a key partnership for the success of Love Pharma's initial product launch.

Company Highlights

  • Love Pharma specializes in sexual health and wellness by distributing products infused with CBD and THC directly to consumers. It holds exclusive licenses to produce, market, package, sell and distribute these patent-protected products throughout North America, the United Kingdom and Europe.
  • The company is investing in creating sustainable long-term sales through strategic distributor partnerships
  • The launch products, Bloom and Auralief, are licensed for retail sales, creating an immediate opportunity for revenue
  • Love Pharma has already planned domestic and international expansion
  • The management team has an established history of success with cannabis and pharmaceutical products
  • The company plans to create research-backed products that make use of psychedelics and nutraceuticals
  • Once the company is publicly listed, plans are already in place to rapidly distribute products and quickly generate revenue
  • Love Pharma completed the acquisition of MicroDoz Theraphy Inc.

Get access to more exclusive Psychedelics Investing Stock profiles here

×